Tirzepatide: Stellar Efficacy Drives Growth, but Payer Precedents and Oral Stumbles Create Risk

Eli Lilly's Q2 Outlook: Strong Growth for Metabolic Portfolio

Eli Lilly is anticipated to report a strong second quarter, potentially exceeding expectations, primarily driven by robust U.S. prescription growth for its tirzepatide profile, including the obesity brand Zepbound and diabetes drug Mounjaro. While the oral weight-loss pill Foundayo, approved on April 1, has seen a slower-than-expected U.S. launch, analysts remain optimistic about its substantial international market potential. The company operates in an obesity market projected to reach $200 billion next year, making it a key focus for investors.

• Strong Performance Expected for Tirzepatide Portfolio: Eli Lilly is projected to achieve a "beat and raise quarter" due to significant U.S. prescription growth for its tirzepatide profile. Both Zepbound, an obesity brand, and Mounjaro, a diabetes drug, are expected to show quarter-on-quarter growth, underscoring the strength of Lilly's established metabolic disease treatments.
• Foundayo's Mixed Launch and International Potential: The oral weight-loss pill Foundayo, which received FDA approval on April 1, is in its first full commercial quarter. Despite a slower-than-anticipated U.S. launch compared to competitors like Novo Nordisk's Wegovy, analysts maintain optimism for Foundayo, particularly highlighting its substantial potential in the international market.
• Strategic Position in a Booming Obesity Market: Eli Lilly is a closely watched company within the rapidly expanding obesity therapeutic space, which is projected to reach up to $200 billion next year. The company's strong portfolio in this area positions it favorably to capitalize on significant market growth and investor interest, despite competitive pressures.

Addressing Unmet Needs Driving Obesity M&A

Recent efforts in obesity and diabetes have increasingly focused on specific, high-risk patient cohorts, particularly older adults and those with multiple comorbidities. Concurrently, major unmet needs have emerged around systemic and practical barriers to care, including medication adherence, financial constraints, and the need for more integrated care models to manage these complex patient profiles.

• Highly Specific Patient Cohorts: The focus has shifted to well-defined populations with complex needs, including older adults (≥65 years) with frailty, individuals with a BMI ≥27 kg/m² and at least one obesity-related complication, and patients requiring integrated management for conditions such as diabetes co-occurring with pulmonary tuberculosis, leprosy, or chronic kidney disease.

• Barriers to Obesity Pharmacotherapy: A primary unmet need is overcoming patient-level barriers to new obesity medications. Key obstacles include financial constraints, with insurance restrictions and cost being major concerns for 38% and 31% of patients, respectively. Furthermore, inconsistent patient-provider communication regarding long-term treatment duration and lifestyle integration limits optimal outcomes.

• Poor Medication Adherence in Diabetes: Medication non-adherence remains a critical challenge in diabetes management, with a pooled prevalence of 48% in some analyses. Predictors of poor adherence are multifactorial and include older age, socioeconomic disadvantage, treatment complexity, psychological distress, polypharmacy, and health-system access barriers.

• Fragmented and Under-Resourced Integrated Care: There is a pressing need to establish effective integrated care models for patients with multimorbidity. Current health systems face systemic barriers, including infrastructure gaps, workforce shortages, and fragmented information systems. This is exemplified by the critically low readiness of tuberculosis facilities in regions like Pakistan to deliver integrated TB-diabetes care due to a lack of routine screening, trained staff, and essential medicines.

• Low Adoption of Biosimilars: A significant unmet need is the low uptake of cost-effective biosimilar insulins despite their potential to reduce financial burdens. For instance, one study of 6,866 patients found that only 3.7% initiated the insulin glargine-yfgn biosimilar, with prescribing patterns, formulary placement, and reimbursement challenges limiting broader adoption.

• Insufficient Patient Engagement: The success of integrated weight management and diabetes care is highly dependent on patient engagement. A key finding indicates that patients must attend four or more weight management visits to achieve significant additional weight loss benefits (-4.4 kg) compared to standard diabetes care alone, highlighting the need for strategies to support patient persistence.

Unpacking Novel Targets from Recent Obesity Acquisitions

Recent literature highlights Glypican 3 (Gpc3) as a novel obesity-responsive gene and emerging molecular target for correcting pathological fat distribution in obesity and its metabolic sequelae. Alongside this preclinical discovery, established non-pharmacological and pharmacological strategies continue to define the current management landscape for insulin resistance and type 2 diabetes.

• Gpc3 discovery and characterization: Identified through integrated proteomic profiling of human subcutaneous and visceral adipose tissues from paired obese/non-obese donors, combined with temporal transcriptomic analysis of mouse adipose stem and progenitor cells (ASPCs) during dietary transitions.

• Depot-specific expression pattern: Gpc3 shows reciprocal expression between subcutaneous and visceral adipose depots in response to dietary cues, positioning it as a regulator of regional adipose plasticity.

• Mechanism of action: Gpc3 modulates canonical Wnt signaling in a depot-specific manner; its loss biases ASPC fate toward adipogenesis over proliferation, implicating it in the control of fat depot expansion.

• Functional validation in vivo: ASPC-specific Gpc3 deletion in mice amplified high-fat diet-induced weight and fat mass gain, with selective enhancement of inguinal white adipose tissue (WAT) expansion, while epididymal WAT remained unaffected — underscoring depot-specific therapeutic potential.

• Development stage: Findings remain at the preclinical stage, derived from mouse models and human tissue profiling studies, with Gpc3 proposed as a target for reprogramming pathological fat distribution.

• Non-pharmacological interventions for insulin resistance: Ketogenic diet, vegetarian/plant-based diet, structured exercise programs, aerobic exercise, CPAP therapy, and electroacupuncture have each demonstrated significant reductions in insulin resistance and improved insulin sensitivity.

• Current pharmacological standard of care: Metformin monotherapy remains the first-line agent for type 2 diabetes, with available drug classes acting primarily by stimulating insulin secretion or enhancing insulin sensitivity; combination therapy is considered when monotherapy fails to achieve therapeutic targets.

The Evolving Obesity Treatment Landscape Post-M&A

The treatment landscape has been significantly reshaped by the ascent of incretin-based therapies, particularly GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. These agents are now established not only for type 2 diabetes (T2DM) and obesity but also for reducing cardiovascular and chronic kidney disease risk in T2DM. Clinical trial data demonstrate impressive, dose-dependent weight loss, with semaglutide 2.4 mg achieving 14.9% to 15.2% reduction and dual-agonist therapy with tirzepatide reaching up to 21.5%. These outcomes are accompanied by significant improvements in glycemic control (HbA1c reductions up to -1.78%) and cardiometabolic parameters, including systolic blood pressure and LDL cholesterol. The safety profile is well-characterized, with common gastrointestinal adverse events like nausea and diarrhea, while serious events such as pancreatitis remain rare, leading to treatment discontinuation rates generally below 15%.

Beyond monotherapy, a key strategic evolution involves combination approaches and the exploration of novel indications. Combining SGLT-2 inhibitors with GLP-1 receptor agonists has been shown to yield superior improvements in HbA1c, body weight, and blood pressure, offering a promising strategy to address residual cardiovascular risk in high-risk populations. Evidence from cardiovascular outcomes trials and real-world studies supports this synergistic effect. Furthermore, the therapeutic potential of GLP-1 RAs is being investigated far beyond metabolic disease. Initial data suggest positive impacts in conditions such as liver disease, neurodegenerative disorders like Parkinson's and Alzheimer's disease, and substance use disorders. For instance, lixisenatide has demonstrated potential in mitigating motor disability progression in early Parkinson's disease, signaling a significant expansion of the clinical utility of this drug class.

While incretin mimetics dominate recent developments, other pharmacological and non-pharmacological modalities continue to evolve. Bariatric surgery remains the most efficacious treatment for severe obesity, setting a high benchmark for pharmacotherapy. In the drug development pipeline, novel agents like polyethylene glycol loxenatide (PEG-Loxe) have shown substantial efficacy in super-obese patients with T2DM, achieving weight reductions up to 21.14 kg and significant HbA1c decreases over 24 weeks. Concurrently, research into dietary interventions highlights the impact of meal sequencing, where consuming vegetables before carbohydrates stabilizes postprandial glucose levels. Alternative approaches such as Traditional Chinese Medicine are also being evaluated for their ability to manage hypoglycemia with fewer adverse effects through multitarget biological mechanisms.